Friday, 16 October 2026European Markets

IBERSOL,SGPS And BAINS MER MONACO Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - ibersol,sgps (ibs.ls) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
ibersol,sgps (ibs.ls) €6.80 10.54% 6.46%
bains mer monaco (bain.pa) €111.00 0.94% 86.62%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ibersol,sgps (ibs.ls)

10.54% forward dividend yield and 6.46% return on equity

ibersol, s.g.p.s., s.a., through its subsidiaries, operates a network of restaurants in portugal, spain, and angola. it operates restaurants under the pizza hut, pasta caffé, pans & company, ribs, frescco, santamaría, kentucky fried chicken, burger king, pans café, pizza móvil, miit, taco bell, sol, silva carvalho catering and palace catering, goto café, and other brands. the company was incorporated in 1985 and is headquartered in porto, portugal. ibersol, s.g.p.s., s.a. is a subsidiary of atps - sgps, s.a.

earnings per share

as for profitability, ibersol,sgps has a trailing twelve months eps of €0.51.

pe ratio

ibersol,sgps has a trailing twelve months price to earnings ratio of 13.33. meaning, the purchaser of the share is investing €13.33 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.46%.

sales growth

ibersol,sgps's sales growth for the current quarter is negative 34.7%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ibersol,sgps's stock is considered to be oversold (<=20).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 16, 2023, the estimated forward annual dividend rate is 0.7 and the estimated forward annual dividend yield is 10.54%.

more news about ibersol,sgps.

2. bains mer monaco (bain.pa)

0.94% forward dividend yield and 86.62% return on equity

société anonyme des bains de mer et du cercle des étrangers à monaco operates in the gaming, hotels, and rental sectors in monaco. the company operates casinos; hotels; restaurants; lounge bars and nightclubs; wellness and leisure facilities; shows and concert halls; shopping centers; and meetings and events centers. it is also involved in the slot machines, table games, and other activities; and rental of residential properties, boutiques, and offices. in addition, the company offers catering services. the company was incorporated in 1863 and is headquartered in monaco.

earnings per share

as for profitability, bains mer monaco has a trailing twelve months eps of €36.56.

pe ratio

bains mer monaco has a trailing twelve months price to earnings ratio of 3.04. meaning, the purchaser of the share is investing €3.04 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 86.62%.

moving average

bains mer monaco's value is higher than its 50-day moving average of €103.41 and way above its 200-day moving average of €91.50.

volume

today's last reported volume for bains mer monaco is 409 which is 51.71% below its average volume of 847.

more news about bains mer monaco.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com